- Ocugen, Inc. (NASDAQ: OCGN) had cash, cash equivalents, and restricted cash of US$115.8 million in Q2, FY21.
- The OCGN stock surged 132.9 percent YTD.
- BioNTech SE (NASDAQ: BNTX) reported a net profit of €2.78 billion in Q2, FY21.
The stocks of Ocugen, Inc. (NASDAQ: OCGN) and BioNTech SE (NASDAQ: BNTX) were trending on Wall Street Monday. The former rose more than 19 percent, and the latter declined around 6 percent in intraday trading.
The OCGN stock was priced at US$8.56 at 1:29 pm ET, up 19.72 percent, while BNTX stock traded at US$327.685 at 1:31 pm ET, down 6.16 percent from their previous close.
Let's look at some of the recent developments of the two companies.
Ocugen, Inc. (NASDAQ: OCGN)
Ocugen, Inc. is a biopharma company based in Pennsylvania. It develops gene therapies for various diseases. Besides, it is also developing a Covid-19 vaccine in collaboration with the Indian company Bharat Biotech.
In December 2020, it partnered with Bharat Biotech to develop Covaxin. The World Health Organization (WHO) is expected to approve the vaccine for emergency use listing (EUL).
On July 9, the companies had submitted the required documents concerning the vaccine to WHO, Bharat Biotech chairman and MD Krishna Ella said.
Ocugen has a market cap of US$1.66 billion, and a forward P/E one year of -28.60. The 52-week highest and lowest stock prices were US$18.77 and US$0.25, respectively.
The trading volume was 4,134,923 on Sep 10. The OCGN stock soared 132.9 percent YTD.
The cash, cash equivalents, and restricted cash of the company were US$115.8 million in Q2, FY21, compared to US$24.2 million in the quarter ended on December 31, 2020. Its loss from operations came in at US$25.61 million, compared to US$3.36 million in the year-ago quarter.
The company reported a net loss of US$25.95 million or a loss of US$0.13 per share, compared to a loss of US$3.61 million or a loss of 0.19 per share in Q2 of fiscal 2020.
BioNTech SE (NASDAQ: BNTX)
The BioNTech SE is a biotechnology firm based in Germany. It manufactures patient-specific immunotherapies.
The company plans to file papers for approval of its Covid-19 vaccine for the age group of 5 to 11 years in September.
Its market cap is US$78.90 billion, the P/E Ratio is 17.03, the forward P/E one year is 9.26, and its EPS is US$19.11. The BNTX stock rose by 307.31 percent YTD.
The 52-week highest and lowest stock prices were US$464.00 and US$58.81, respectively. Its share volume on September 10 was 3,037,842.
The total revenue of the company was €5.30 billion (euros) in Q2, FY21, compared to €41.7 million in the year-ago quarter. Its profit for the period came in at €2.78 billion compared to a loss of €88.3 million in Q2, FY20.
The healthcare sector has been one of the main focuses of investors in recent days, mainly due to the Covid-19 vaccines. Last Thursday, President Joe Biden said it is mandatory for all private sector companies having over 100 employees to vaccinate fully and regularly test all staff members. The S&P 500 index’s healthcare segment rose 17.01 percent YTD and 5.46% QTD.